Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802759 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
A Phase 1 study of Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 316
- Enrollment target
- 20
- Study locations
NCT04802759: Recruiting Phase 1 study of Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, sponsored by Hoffmann-La Roche.
NCT04802759 is a Phase 1 study of Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 316 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (427% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04802759, a Phase 1 study of Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 316 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER+, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib, or neratinib). Cohort 3 will focus on inoperable, locally advanced or metastatic, ER+, HER2-negative, PIK3CA-mutated breast cancer with resistance to adjuvant endocrine therapy.
Conditions Studied
Interventions
- DRUG Ipatasertib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG Inavolisib
- DRUG Giredestrant
Study Locations (20)
California
- City of Hope - Duarte
- University of California, San Francisco (UCSF) - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Santa Monica
- Stanford Cancer Institute (SCI) - Stanford
Other
- Rambam Medical Center - Haifa
- Hadassah Ein Karem Hospital - Jerusalem
- Rabin MC - Petah Tikva
- The Chaim Sheba Medical Center - Ramat Gan
New Jersey
- Regional Cancer Care Associates LLC (RCCA) - Freehold Location - Freehold
- Regional Cancer Care Associates LLC ? Howell Division - Howell Township
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
Victoria
- Peninsula Health-Frankston Hospital - Frankston
- Peter Maccallum Cancer Centre - Melbourne
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- Levine Cancer Institute - Charlotte
Tennessee
- West Cancer Center - Germantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2029-05-30 |
| Phase | Phase 1 |
What NCT04802759 shows while recruiting
NCT04802759 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (427% higher).
The record links to 1 condition, with Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Ipatasertib is the first listed.
NCT04802759 names 20 study sites across 11 states, led by California, Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04802759 about?
NCT04802759 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer". This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unaccept...
What is the current status of trial NCT04802759?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 316 participants. The study started on 2021-06-22. Estimated completion is 2029-05-30.
What conditions does trial NCT04802759 study?
This clinical trial studies the following conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer.
What interventions are being tested in trial NCT04802759?
The interventions under investigation include: Ipatasertib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), Inavolisib (DRUG), Giredestrant (DRUG).
Who is sponsoring clinical trial NCT04802759?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04802759 being conducted?
This trial has 20 study locations across California, Massachusetts, New Jersey, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04802759's enrollment target sits among peer trials
316 117th of 2000 higher than 1,884 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
- NCT05692973 · 316 participants · NA
The Role of Knowledge Retrieval in Inference-making
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI